Loading
A phase 1/2 trial of YH32367 in advanced solid tumours, run by Yuhan Corporation, now recruiting.
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor is a phase 1/2 interventional study registered as NCT05523947 by Yuhan Corporation, with 147 participants planned, started 2022-08-26 and due to reach its primary completion in 2028-03-31. Interventions recorded: YH32367.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Yuhan Corporation, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Yuhan Corporation, HER2 and the tag pipeline.
Shares HER2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HER2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HER2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/